Obesity Featured Articles

  1. Crafting The Vision: Building A Strong Value Story For Biotechs 1/14/2026

    Early-stage biotechs need more than science — they need a clear vision. Learn to craft a value story that shows differentiation, market potential, and patient impact to attract investors and partners.

  2. Big Futures For Emerging Biopharma: Navigating Biotech Hurdles 1/14/2026

    Emerging biopharma drives agile, data-driven, patient-focused drug development. Discover how to overcome complexity, speed timelines, and thrive in a fast-changing healthcare landscape.

  3. Accelerating Parkinson's Disease Clinical Research Through CHDR's Monocentre Recruitment Capabilities 1/14/2026

    Centralized PD trials reduce variability, accelerate enrolment, and enable genetic stratification for targeted therapies. This streamlined model delivers high-quality data and faster timelines, helping sponsors move confidently from early-phase research to late-stage development.

  4. Scout's Science-Based Targets Commitment: What Comes Next 1/14/2026

    Explore the latest Science Based Targets initiative commitment, clarifying what has been approved, what remains in progress, and the steps required before emissions reduction targets can be validated.

  5. Confronting "Time Toxicity" In Global Oncology And Rare Disease Trials For Operational Excellence And Patient Retention 1/14/2026

    Time is the only truly finite resource in a clinical trial. Consultant Leila Cupersmith discusses how sponsors can better design trials with a lower time burden to boost enrollment, retention, and overall operational excellence.

  6. From Lab To Launch: Navigating The Transition To Commercial Readiness 1/13/2026

    Many clinical-stage companies start thinking about commercialization too late. FTI Consulting experts team up to provide guidance on getting started early.

  7. Navigating The Enrollment Bottleneck In Early Oncology Trials 1/12/2026

    Slow oncology trial enrollment raises costs and delays progress. AI prescreening, patient-focused engagement, and early pharmacology studies help accelerate recruitment and optimize trial design.

  8. Working (Well) With Patient Advocates: The Sponsor POV 1/12/2026

    Aeovian CEO Allison Hulme reflects on Aeovian Pharmaceuticals' partnership with the TSC Alliance and how it’s informed research and development of their first-in-class selective mTORC1 inhibitor. 

  9. Virtual Reality Endpoints Improve Measurement Of Patients' Real-World Benefit 1/12/2026

    Opus Genetics CEO George Magrath, MD, discusses how the company introduced virtual reality-enabled assessments and relied on digital endpoints to better measure participants’ vision changes.

  10. Working (Successfully) With Pharma: A PAG's Perspective 1/12/2026

    TSC Alliance President and CEO Kari Rosbeck details the patient advocacy group's unique and fruitful relationship with Aeovian Pharmaceuticals in developing the company's first-in-class selective mTORC1 inhibitor for TSC-related refractory epilepsy.